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Background. Moderate alcohol consumption is thought
to confer cardiometabolic protective effects. Inflam-
matory pathways are hypothesized to partly under-
lie this association.
Objectives. The aim of this study was to examine the
association between typologies of alcohol con-
sumption and markers of inflammation, and their
rate of change over time.
Methods. Data were collected from 8209 participants
[69% men; mean age, 50 years (SD 6.1)] of the
British Whitehall II study. Alcohol consumption
typologies were defined using up to three measures
during an approximately 10-year period spanning
from 1985 to 1994 as (i) stable nondrinkers, (ii)
stable moderate drinkers (referent), (iii) stable
heavy drinkers, (iv) nonstable drinkers and (v)
former drinkers. C-reactive protein (CRP), inter-
leukin (IL)-6 and IL-1 receptor antagonist (IL-1 RA)
were measured up to three times in the following
12 years.
Results. Stable moderate drinkers had lower levels of
CRP than stable nondrinkers, stable heavy drin-
kers, former drinkers and nonstable drinkers, but
there were no differences in the rate of change in
CRP over time between groups. Stable nondrinkers
had higher levels of IL-6 as did stable heavy
drinkers; rates of change in IL-6 over time were also
increased in the latter group. Stable nondrinkers
also had higher levels of IL-1 RA. These associations
were robust to adjustment for confounding factors.
Conclusion. Our novel investigation of 10-year drink-
ing typologies shows that stable moderate alcohol
consumption is associated with a long-term inflam-
matory marker profile that is consistent with
conferring a reduced risk of developing coronary
heart disease.
Keywords: alcohol, cytokines, epidemiology, inflam-
mation, longitudinal.
Introduction
Moderate alcohol consumption is thought to confer
cardiometabolic protective effects [1–3] and has
also been demonstrated to be related to a lower risk
of a plethora of other disorders of different aetiology
compared to both no alcohol and heavy alcohol
intake [4]. Numerous biological mechanisms have
been put forward to explain the proposed car-
diometabolic protection [5, 6], with favourable
changes in high-density lipoprotein (HDL) choles-
terol, fibrinogen and adiponectin supported by
evidence from several small-scale randomized con-
trolled feeding trials [7]. However, these factors are
unlikely to entirely explain the protective effects
observed for moderate consumption and car-
diometabolic outcomes compared to abstinence
(or the increased risk observed amongst heavier
drinkers), and their causal role in the aetiology of
cardiovascular disease (CVD) remains unclear [8–
14].
Therefore, if the protective cardiometabolic effects
observed are genuine, it is likely that other
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biological pathways are involved, one of which may
be via pro-inflammatory cytokines [15]. For exam-
ple, higher levels of the acute-phase reactant C-
reactive protein (CRP) are associated with an
increased risk of developing CVD [16] and a variety
of other disease end-points [17]. Studies have
demonstrated that higher levels of interleukin
(IL)-6 are associated with an increased risk of
coronary heart disease (CHD) [18], including stud-
ies examining long-term exposure to elevated IL-6
[19] or functional genetic variants of IL-6 signalling
[20], suggesting that the association is causal. IL-1
is considered a master regulator of inflammation
that triggers the release of a variety of inflamma-
tory markers through activating the IL-1 receptor.
The IL-1 receptor antagonist (IL-1 RA) is an
endogenous inhibitor of IL-1 that prevents the
activation of the IL-1 receptor by either IL-1a or
IL-1b [21]. IL-1 RA is associated with a diverse
range of diseases including CVD, type 2 diabetes,
certain cancers and joint diseases such as arthritis
[21–25]. In a recent large-scale Mendelian random-
ization study, it was found that genetically elevated
levels of IL-1 RA were causally associated with an
increased risk of CHD and abdominal aortic
aneurysm [26].
The findings of studies investigating alcohol con-
sumption and inflammatory markers have been
mixed. There is limited and conflicting evidence
from interventional studies, typically with sample
sizes of <100 participants and over relatively short
periods of time, of the association between alcohol
consumption and inflammation [7, 27–29]. In
terms of observational studies, some investigators
have found that moderate alcohol consumption is
associated with lower levels of CRP [30–32] and IL-
6 [32, 33] compared to no alcohol and heavy
alcohol intake, whereas others have observed no
association [33, 34]. Studies of the association
between alcohol intake in the general population
and IL-1 RA are scarce [33].
Furthermore, most previous studies have only
used a single measure of alcohol intake at baseline
to define the drinking behaviour of participants,
assuming that it is static thereafter. However,
individuals’ drinking habits change over time [35,
36], and this can affect their risk of developing
disease [37]. Therefore, not accounting for long-
term drinking profiles or changes in alcohol con-
sumption can introduce bias [38–40]. A classic
example of such bias is the failure to separate
former drinkers from never drinkers which is
known to in some cases substantially impact
findings and subsequent conclusions that are
drawn [41, 42]. Levels of CRP, IL-6 and IL-1 RA
also change over time and can similarly influence
disease risk [25, 43, 44].
In summary, studies utilizing repeat measures of
alcohol consumption [35] or examining the influ-
ence of alcohol on the change in biomarker levels
over time [45] are rare. Studies combining these
two elements are nonexistent. We therefore aimed
to examine the association between typologies of
alcohol consumption over an approximately 10-
year period and markers of inflammation, includ-
ing CRP, IL-6 and IL-1 RA, and their rate of change
over the following 12 years.
Materials and methods
Study population
Data were obtained from the Whitehall II cohort of
British civil servants [46]. The study started
during the period 1985–1988 (phase 1) and
included 10 308 participants (6895 men) aged
35–55 years. All civil servants within this age
range in 20 London-based departments were
invited by letter to participate, and 73% agreed.
The first phase involved a clinical examination as
well as a self-administered questionnaire to collect
information on demographic characteristics,
health, lifestyle factors, work characteristics,
social support and life events. Subsequent phases
of data collection have alternated between postal
questionnaire alone and postal questionnaire
accompanied by a clinical examination. Data used
in this investigation were from phases 1
(1985–1988), 2 (1989–1990), 3 (1991–1994), 5
(1997–1999) and 7 (2002–2004) of the study. The
maximum available sample was 8209 participants
for whom there was information on alcohol con-
sumption, age and gender, and at least one
measure of CRP, IL-6 or IL-1 RA.
Ethical considerations and data access
The University College London Medical School
committee on the Ethics of Human Research
approved the Whitehall II study. Informed consent
was obtained at baseline and renewed at each
contact. Whitehall II study data, protocols and
other metadata are available to bona fide research-
ers for research purposes (data sharing policy is
available at http://www.ucl.ac.uk/whitehallII/
data-sharing).
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Assessment of alcohol consumption
We used alcohol information collected at study
phases 1, 2 and 3 to construct (approximately) 10-
year drinking typologies. Participants were asked
to report the number of alcoholic drinks they had
consumed in the previous week, providing infor-
mation separately for beer/cider (in pints), wine (in
glasses) and spirits (in measures). Drinks were
converted into grams of ethanol using a conserva-
tive estimate of 8 g for each measure of spirits and
glass of wine, and 16 g for each pint of beer [47].
The sum of these converted measurements was
then used to define total weekly amount of alcohol
intake in grams. We then constructed categories of
alcohol consumption based on UK guidelines for
sensible drinking at the time: none, moderate
(within guidelines of 8–168 g ethanol per week for
men and 8–112 g for women) and heavy (intake
above these guidelines).
Typologies of drinkers to remain in keeping with the
results over studyphases1–3weredefinedas follows:
stable nondrinkers, stable moderate drinkers, stable
heavydrinkers, nonstable drinkers (participantswho
moved between categories of consumption during
observation) and former drinkers [nondrinkers at
study phase 3 who had previously reported consum-
ing alcohol (at any level) at earlier study phases].
Participants were permitted one missing alcohol
value in the construction of the 10-year alcohol
typology variable. Our reference group for analyses
was stable moderate drinkers [48].
Assessment of inflammatory markers
Fasting serum samples were collected between
08.00 and 13.00, stored at 80°C and were not
thawed or refrozen during storage. Although serum
samples were from three different study phases,
blood collection, processing and storage followed
the same standard operating procedures.
CRP was measured with a high-sensitivity
immunonephelometric assay in a BN ProSpec
nephelometer (Dade Behring, Milton Keynes, UK).
IL-6 was measured with a high-sensitivity enzyme-
linked immunosorbent assay (ELISA) (R&D Sys-
tems, Oxford, UK). Values lower than the detection
limit [0.154 mg L1 for CRP (multiplied by 9524 to
express the value in mmol L1) and 0.08 pg mL1
for IL-6] were assigned a value equal to half the
detection limit. We excluded samples with CRP
concentrations suggestive of acute inflammation
and related bacterial infection (>10 mg L1) [49]
(n = 242). To measure short-term biological varia-
tion and laboratory error, a repeat sample was
taken from 150 participants for CRP and 241
participants for IL-6 at phase 3 [with a mean
elapsed time between samples of 32 days (SD
10.5)]. Intra-assay and interassay coefficients of
variation were 4.7% and 8.3% for CRP and 7.5%
and 8.9% for IL-6, respectively.
Serum IL-1 RA was measured in a diabetes case–
cohort sample [25, 50] with the Quantikine ELISA
kit (R&D Systems, Wiesbaden, Germany). All
assays were performed consecutively in the same
laboratory (German Diabetes Center), and samples
from different study phases from the same partic-
ipant were always measured using the same ELISA
plate to minimize assay imprecision. Mean intra-
assay and interassay coefficients of variation were
2.6% and 7.9%, respectively. The limit of detection
was 14 pg mL1 (all samples were above the limit
of detection).
Covariates
Age, sex, ethnicity (White or non-White), prevalent
CHD (clinically verified events) and type 2 diabetes
(cases defined by oral glucose tolerance tests and/
or use of diabetes medication) at study phase 3
were entered into our statistical models as time-
invariant predictors.
Time-varying covariates included in our models
were socio-economic position [defined using either
current or last recorded civil service employment
grade as high (unified grades 1–7), intermediate
(executive officers) or low (clerical or support staff),
as previously described [51]] and health beha-
viours including smoking status (never, former and
current) and physical activity (lowest sex-specific
quartile of combined hours of moderate and vigor-
ous physical activity defined as ‘physically inac-
tive’). Diet quality was classified as poor or good
using three questions on the type of milk and bread
participants usually consumed and their frequency
of fruit and vegetable intake. For each dietary
component, a score of one was assigned to poor
diet quality indicators (whole milk, white bread,
fruit and vegetable intake less than daily), and a
summed score ≥2 was used to classify poor diet
quality [52]. Body mass index (BMI) was calculated
using the standard formula, and participants were
classified as normal weight (18.5–24.9 kg m2),
overweight/obese (≥25 kg m2) or underweight
S. Bell et al. Alcohol and cytokine trajectories
ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. 77
Journal of Internal Medicine, 2017, 281; 75–85
(<18.5 kg m2) using thresholds adopted by the
World Health Organisation.
Statistical analysis
Differences in sample characteristics by drinking
typologies were assessed using chi-square test or
one-way ANOVA. To examine the association between
alcohol typologies and trajectories of inflammatory
markers, we used linear mixed models with time
from phase 3 in years as the time metric (allowing
for individually varying times of observation). We
included random effects for the intercept and time
and allowed for random effects to covary. As CRP,
IL-6 and IL-1 RA were positively skewed, we used
natural logarithm-transformed values in all analy-
ses (predictions were calculated using these mod-
els and then back-transformed to their original
scale for graphical presentation). Preliminary anal-
yses revealed no evidence of effect modification
between drinking typologies and sex in the rate of
change in any inflammatory marker. Therefore,
two models are presented for each outcome, one
with adjustments only for age and sex and the
other with adjustments for all covariates described
above. These models include terms for the differ-
ence in inflammatory markers at study phase 3 by
alcohol group (intercept differences) as well as
interactions between drinking categories and time
to describe differences in the rate of change in
inflammatory markers per year of follow-up by
alcohol typologies. We also include analyses with
alcohol intake categories defined using data from
phase 3 assessment only, presented in the Online
Supplementary Material, so that findings from the
main analysis can be compared to those that would
have been obtained using the conventional
approach of only using alcohol intake assessed at
one time-point (as in the main analyses presented,
these models include terms describing differences
in baseline values of inflammatory markers as well
as their rate of change over time). An a level of
<0.05 was considered statistically significant. All
analyses were conducted using Stata 14.1 Stata-
Corp (College Station, Texas, USA).
Results
Descriptive statistics
The characteristics of participants at study phase 3
are presented in Table 1. The mean age of partic-
ipants was 50 years (SD 6.1). Almost 70% of the
participants were men, and the majority were of
White ethnicity and high or intermediate
socio-economic position. Approximately half of
the participants had never smoked whilst 14% were
current smokers. The majority of participants were
physically active and made good dietary choices.
Half of the sample had a BMI considered to be in the
normal range, and 47%were considered overweight.
Prevalent CHD (3%) or type 2 diabetes (1%) was rare
amongst participants. During follow-up, there were
696 and 873 incident cases of CHD and type 2
diabetes, respectively. Descriptive statistics for
changes in alcohol consumption and inflammatory
markers are presented in Table S1.
Ten-year drinking typologies
Regression coefficients of the associations between
10-year alcohol typologies and trajectories of CRP,
IL-6 and IL-1 RA are shown in Table 2.
In multivariable-adjusted models, all drinking
typologies other than former drinkers had statisti-
cally significantly elevated levels of CRP at phase 3
in comparison with stable moderate drinkers. No
drinking groups differed significantly in their rate
of change in CRP over time.
All drinking typologies had elevated levels of IL-6 at
phase 3 compared to moderate drinkers in the
multivariable-adjusted model (10.4% [95% confi-
dence interval (95% CI), 4.9–16.3] higher in stable
nondrinkers, 11.5% [95% CI, 6.2–17.0] higher in
stable heavy drinkers and 9.3% [95% CI, 4.5–14.5]
higher in former drinkers). Stable heavy drinkers
also showed increases in the rate of change in IL-6
levels over time [0.9% (95% CI 0.3–1.4) per year].
Nonstable drinkers had slightly shallower
increases in their rate of change in IL-6 over time
[0.4% (95% CI, 0.7 to ~0.0)] compared to moder-
ate drinkers.
Stable nondrinkers had elevated levels of IL-1 RA
compared to moderate drinkers at phase 3 [6.7%
(95% CI, 0.7–13.1)]. No significant effects on the
levels of IL-1 RA were observed for any other
drinking typology, nor were any significant effects
observed for any drinking typology on the rate of
change in IL-1 RA over time.
The mean trajectories of each biomarker, predicted
using the multivariable model, by drinking typol-
ogy are presented graphically in Fig. 1.
Findings based on drinking information alone at
study phase 3 were similar to those observed using
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10-year drinking typologies (Table S2 and Fig-
ure S1). However, whilst the findings were broadly
concordant, those based on information on drink-
ing behaviour over a 10-year period revealed that
participants with a sustained history of heavy
drinking had higher levels of inflammation as well
as steeper increases in IL-6 values than were seen
when using current drinking information alone. As
a post hoc analysis suggested by reviewers for
further comparison with evidence from small-scale
feeding trials [28], we repeated the analysis for
changes in fibrinogen during an average period of
~5 years. We found that compared to moderate
drinkers, both former drinkers and stable non-
drinkers had higher levels throughout follow-up.
Conversely, heavy drinkers had, on average, the
lowest levels of fibrinogen during observation
(Tables S3, S4 and Figure S2).
Discussion
Summary of findings
We observed that those who consistently con-
sumed alcohol at levels considered moderate over
a 10-year period had lower concentrations of CRP,
IL-6 and IL-1 RA compared to nondrinkers during
the following 12 years. Former drinkers also had
higher levels of each of these markers during this
period, although this association was not statisti-
cally significant. Additionally, we found that heavy
drinkers not only had increased levels of these
cytokines compared to stable moderate drinkers,
but also demonstrated a more marked rate of
change in IL-6 levels over time.
Interpretation, comparison to other work and implications
Our findings are broadly consistent with the U- or
J-shaped associations observed between alcohol
consumption and cardiometabolic outcomes.
Thus, we found that nondrinkers, former drinkers
and heavy drinkers had consistently elevated levels
of CRP, IL-6 and IL-1 RA over a 12-year period.
These findings are supported by evidence from
other studies of the effect of alcohol consumption
on inflammatory markers [30, 31]. Two of these
markers (IL-6 and IL-1 RA) are believed to be
causally associated with CHD, providing indirect
evidence that moderate alcohol consumption may
confer some cardioprotective effects. The mecha-
nisms by which alcohol achieves this are unknown,
but may involve mild activation of inflammatory
pathways, which confer some benefit. On the other
hand, these pathways are also likely to be involved
in the detrimental effects of heavy drinking. These
observations are concordant with large-scale Men-
delian randomization studies that have shown that
inhibiting IL-6 signalling could reduce the risk of
developing CHD [53] whilst inhibiting IL-1 a/bmay
increase the risk of CHD [26]. This highlights not
only the complexity of inflammatory pathways
underlying CVDs but also the complicated role of
alcohol consumption in the development of such
diseases. For example, moderate alcohol intake
Fig. 1 Model-predicted C-
reactive protein, interleukin-6
and interleukin-1 receptor
antagonist trajectories by 10-
year drinking typologies.
Multivariable adjustment for
age, sex, ethnicity, prevalent
coronary heart disease or type
2 diabetes at phase 3, socio-
economic position, smoking
status, physical activity, diet
and body mass index. Graphs
are based on the back
transformation of log-
transformed C-reactive protein,
interleukin-6 and interleukin-1
receptor antagonist predicted
by linear mixed models
(Table 2).
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may induce oxidative stress by induction of partic-
ular heat shock proteins, which inhibit the activa-
tion of various pro-inflammatory cytokines leading
to endotoxin tolerance [54]. Endotoxin tolerance is
thought to be a protective mechanism against
developing coronary occlusion and acute coronary
syndromes [55], and may explain why moderate
drinkers have a lower risk of CHD than non-
drinkers. By contrast, a pattern of heavy alcohol
use may lead to low-level gut bacterial transloca-
tion and consequent increased levels of pro-inflam-
matory cytokines. It was recently demonstrated
that an acute alcohol ‘binge’ of 0.8 g kg1 in
healthy individuals led to a rapid increase in serum
endotoxin and bacterial DNA, as well as increased
acute-phase protein levels and pro-inflammatory
cytokine responses [56]. This pattern of low-level
bacterial translocation has been associated with
disease progression in animal models of obesity
and metabolic syndrome [57, 58].
In terms of overall effect sizes, the multivariable-
adjusted effect of stable nondrinking on the inter-
cept of IL-6 is equivalent to the per-allele effect of
single nucleotide polymorphism (SNP) rs7529229
in the IL6R gene (Ch1q21.3) on IL-6 levels [53]
which confers an approximately 5% reduction in
odds of developing CHD. CRP levels were
increased by 15.7% in nondrinkers compared to
stable moderate drinkers, which is similar to the
per-allele difference observed for CRP SNP
rs1130864 [59]. However, this elevated level of
CRP has been shown not to confer a protective or
detrimental effect for CHD [59]. The effect of
nondrinking on IL-1 RA although statistically
significant was relatively small, and less than the
effect observed for a genetic allele count score
using two common, uncorrelated, SNPs
(rs6743376 and rs1542176) located upstream of
ILRN (the gene that encodes the IL-1 RA) [26].
Given that a per-allele increase in this genetic
score was only associated with a 3% increase in
the odds of developing CHD and not significantly
associated with developing type 2 diabetes [26],
the relative contribution of moderate drinking to a
reduced risk of CHD via IL-1 a/b is likely to be
minimal.
Our longitudinal approach demonstrates the
importance of accounting for repeat measures of
alcohol intake when estimating associations with
health outcomes [35]. We found that only con-
sidering alcohol consumption at one point in time
led to underestimation of the effect of heavy
drinking on inflammatory markers. Furthermore,
we observed that former drinkers had higher
levels of cytokines than stable nondrinkers, in
keeping with the idea that failing to exclude
former drinkers from the group of stable non-
drinkers will lead to overestimating the protective
effect of moderate drinking [42]. This group may
consist of former heavy drinkers (including indi-
viduals with a history of alcohol use disorders)
and those with illnesses that have led to alcohol
cessation [60], both of which are likely to be
associated with higher levels of inflammation [61–
63]. However, it is also worth noting that amongst
those with existing illness, alcohol abstinence is
generally associated with better long-term prog-
nosis than continued drinking [64, 65]. Further-
more, whilst it has been shown that CVD risk
factors are more common in nondrinkers [66],
even when lifelong nondrinkers can be separated
from former and occasional drinkers, ill-health
prior to the age at which alcohol consumption
typically begins has been shown to be more
common in those who have never consumed
alcohol [67]. All of these factors may contribute
to higher levels of inflammation as well as
increased risk of CVD in nondrinkers. As such,
the protective effect of moderate drinking on
cardiometabolic outcomes is likely to be more
modest than is often believed [41, 68].
Strengths and weaknesses
Our study has several strengths including the large
sample size and use of repeat measures of alcohol
consumption to define alcohol typologies over a 10-
year period (reducing drinking category misclassi-
fication bias inherent in studies utilizing only one
measure of alcohol consumption) as well as repeat
measures of markers of inflammation.
However, there are also several shortcomings. For
example, it is known that heavy drinkers are
underrepresented in population-level surveys; the
drinkers in our sample are typically low-to-moder-
ate consumers [35]. This means that the effect we
observed for heavy drinking on trajectories of
inflammatory markers is likely to be an underes-
timate of the ‘true’ association.
Another limitation is that we used self-reported
measures of alcohol consumption which have
been criticized [69]. Furthermore, we focused on
total weekly quantity of alcohol intake, not
changes in both frequency and quantity. It is
S. Bell et al. Alcohol and cytokine trajectories
82 ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Journal of Internal Medicine, 2017, 281; 75–85
plausible that shifts in pattern of consumption
may better explain differences in risk of CHD over
time [70]. However, this does not affect our
comparison with existing work which has also
mostly focused on singular components of drink-
ing behaviour (also largely overall weekly quantity
of alcohol consumption).
Finally, participants in theWhitehall II study arenot
a representative sample of the general population;
however, it has been shown that cardiometabolic-
related aetiological findings from this cohort are
broadly consistent with those obtained from repre-
sentative cohorts [71].
Conclusion
Stable moderate alcohol consumption is associated
with a shift in the long-term inflammatory marker
profile which is consistent with conferring a
reduced risk of developing CHD. The implication
of this is that modulation of chronic inflammation
is a significant pathway through which alcohol
affects overall CHD risk.
Conflict of interest statement
No conflicts of interest to declare.
Acknowledgements
We would like to thank all participating study
members and all members of the Whitehall II study
team. In addition, we thank the two anonymous
referees for their careful reading of our origi-
nal manuscript and helpful suggestions for
improvement.
Sources of funding
This work was supported by grants from the
European Research Council (ERC-StG-2012-
309337_AlcoholLifecourse, PI: Annie Britton,
http://www.ucl.ac.uk/alcohol-lifecourse) and UK
Medical Research Council/Alcohol Research UK
(MR/M006638/1). The Whitehall II study was
supported by grants from the UK Medical Research
Council (K013351), British Heart Foundation (RG/
07/008/23674), Stroke Association, National
Heart Lung and Blood Institute (HL036310) and
National Institute on Aging (AG13196, AG034454).
The funders had no role in the design of the study,
data collection and analysis, or the preparation of
and decision to publish the manuscript.
Author contributions
SB and AB conceived the research question. SB
carried out the analysis. SB completed the first
draft of the manuscript. AB, GM and KM provided
additional intellectual content. All authors read
and agreed on the final submitted manuscript.
References
1 Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA.
Association of alcohol consumption with selected cardiovas-
cular disease outcomes: a systematic review and meta-
analysis. BMJ 2011; 342: d671.
2 Gemes K, Janszky I, Laugsand LE et al. Alcohol consumption
is associated with a lower incidence of acute myocardial
infarction: results from a large prospective population-based
study in Norway. J Intern Med 2016; 279: 365–75.
3 Roerecke M, Rehm J. The cardioprotective association of
average alcohol consumption and ischaemic heart disease: a
systematic review and meta-analysis. Addiction 2012; 107:
1246–60.
4 Fekjær HO. Alcohol—a universal preventive agent? A critical
analysis Addiction 2013; 108: 2051–7.
5 Mathews M, Liebenberg L, Mathews E. The mechanism by
which moderate alcohol consumption influences coronary
heart disease. Nutr J 2015; 14: 33.
6 Movva R, Figueredo VM. Alcohol and the heart: to abstain or
not to abstain? Int J Cardiol 2013; 164: 267–76.
7 Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA.
Effect of alcohol consumption on biological markers associ-
ated with risk of coronary heart disease: systematic review
and meta-analysis of interventional studies. BMJ 2011; 342:
d636.
8 Holmes MV, Asselbergs FW, Palmer TM et al. Mendelian
randomization of blood lipids for coronary heart disease. Eur
Heart J 2014; 36: 539–50.
9 Barter PJ, Caulfield M, Eriksson M et al. Effects of Torce-
trapib in patients at high risk for coronary events. N Engl J
Med 2007; 357: 2109–22.
10 Yaghootkar H, Lamina C, Scott RA et al. Mendelian randomi-
sation studies do not support a causal role for reduced
circulating adiponectin levels in insulin resistance and type 2
diabetes. Diabetes 2013; 62: 3589–98.
11 Keavney B, Danesh J, Parish S et al. Fibrinogen and coronary
heart disease: test of causality by “Mendelian randomization”.
Int J Epidemiol 2006; 35: 935–43.
12 Sook Lee E, Park S, Kim E et al. Association between
adiponectin levels and coronary heart disease and mortality:
a systematic review and meta-analysis. Int J Epidemiol 2013;
42: 1029–39.
13 Borges MC, Lawlor DA, de Oliveira C, White J, Horta B,
Barros AJ. The role of Adiponectin in Coronary Heart Disease
Risk: a Mendelian Randomization Study. Circ Res 2016; 119:
491–9.
14 Burgess S, Harshfield E. Mendelian randomization to assess
causal effects of blood lipids on coronary heart disease:
lessons from the past and applications to the future. Curr
Opin Endocrinol Diabetes Obes 2016; 23: 124–30.
S. Bell et al. Alcohol and cytokine trajectories
ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. 83
Journal of Internal Medicine, 2017, 281; 75–85
15 Imhof A, Koenig W. Alcohol inflammation and coronary heart
disease. Addict Biol 2003; 8: 271–7.
16 The Emerging Risk Factors Collaboration. C-reactive protein,
fibrinogen, and cardiovascular disease prediction. N Engl J
Med 2012; 367: 1310–20.
17 Ansar W, Ghosh S. C-reactive protein and the biology of
disease. Immunol Res 2013; 56: 131–42.
18 Kaptoge S, Seshasai SRK, Gao P et al. Inflammatory cytoki-
nes and risk of coronary heart disease: new prospective study
and updated meta-analysis. Eur Heart J 2014; 35: 578–89.
19 Danesh J, Kaptoge S, Mann AG et al. Long-term interleukin-6
levels and subsequent risk of coronary heart disease: two new
prospective studies and a systematic review. PLoS Med 2008;
5: e78.
20 IL6R Genetics Consortium Emerging Risk Factors Collabora-
tion. Interleukin-6 receptor pathways in coronary heart
disease: a collaborative meta-analysis of 82 studies. Lancet
2012; 379: 1205–13.
21 Dinarello CA, Simon A, van der Meer JWM. Treating inflam-
mation by blocking interleukin-1 in a broad spectrum of
diseases. Nat Rev Drug Discov 2012; 11: 633–52.
22 Garlanda C, Dinarello CA, Mantovani A. The interleukin-1
family: back to the future. Immunity 2013; 39: 1003–18.
23 VanTassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting
interleukin-1 in heart disease. Circulation 2013; 128: 1910–
23.
24 Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1
receptor antagonist gene polymorphism on disease. Clin
Infect Dis 2002; 34: 204–9.
25 Carstensen M, Herder C, Kivim€aki M et al. Accelerated
increase in serum interleukin-1 receptor antagonist starts 6
years before diagnosis of type 2 diabetes: Whitehall II
prospective cohort study. Diabetes 2010; 59: 1222–7.
26 The Interleukin 1 Genetics Consortium. Cardiometabolic
effects of genetic upregulation of the interleukin 1 receptor
antagonist: a Mendelian randomisation analysis. Lancet
Diabetes Endocrinol 2015; 3: 243–53.
27 Chiva-Blanch G, Magraner E, Condines X et al. Effects of
alcohol and polyphenols from beer on atherosclerotic
biomarkers in high cardiovascular risk men: a randomized
feeding trial. Nutr Metab Cardiovasc Dis 2015; 25: 36–45.
28 Stote KS, Tracy RP, Taylor PR, Baer DJ. The effect of moderate
alcohol consumption on biomarkers of inflammation and
hemostatic factors in postmenopausal women. Eur J Clin Nutr
2016; 70: 470–4.
29 Chiva-Blanch G, Urpi-Sarda M, Llorach R et al. Differential
effects of polyphenols and alcohol of red wine on the expres-
sion of adhesion molecules and inflammatory cytokines
related to atherosclerosis: a randomized clinical trial. Am J
Clin Nutr 2012; 95: 326–34.
30 Imhof A, Woodward M, Doering A et al. Overall alcohol intake,
beer, wine, and systemic markers of inflammation in western
Europe: results from three MONICA samples (Augsburg,
Glasgow, Lille). Eur Heart J 2004; 25: 2092–100.
31 Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig
W. Effect of alcohol consumption on systemic markers of
inflammation. Lancet 2001; 357: 763–7.
32 Volpato S, Pahor M, Ferrucci L et al. Relationship of alcohol
intake with inflammatory markers and plasminogen activator
inhibitior-1 in well-functioning older adults: the Health,
Aging, and Body Composition Study. Circulation 2004; 109:
607–12.
33 Marques-Vidal P, Bochud M, Bastardot F et al. Associations
between alcohol consumption and selected cytokines in a
Swiss population-based sample (CoLaus study). Atheroscle-
rosis 2012; 222: 245–50.
34 Hamer M, Stamatakis E. The accumulative effects of modifi-
able risk factors on inflammation and haemostasis. Brain
Behav Immun 2008; 22: 1041–3.
35 Britton A, Ben-Shlomo Y, Benzeval M, Kuh D, Bell S. Life
course trajectories of alcohol consumption in the United
Kingdom using longitudinal data from nine cohort studies.
BMC Med 2015; 13: 47.
36 Britton A, Bell S. Reasons why people change their alcohol
consumption in later life: findings from the Whitehall II
Cohort Study. PLoS One 2015; 10: e0119421.
37 Britton A, Marmot MG, Shipley MJ. How does variability in
alcohol consumption over time affect the relationship with
mortality and coronary heart disease? Addiction 2010; 105:
639–45.
38 Greenfield TK, Kerr WC. Commentary on Liang & Chikritzhs
(2011): quantifying the impacts of health problems on drink-
ing and subsequent morbidity and mortality – life-course
measures are essential. Addiction 2011; 106: 82–3.
39 Bell S, Britton A. The role of alcohol consumption in regulat-
ing circulating levels of adiponectin: a Prospective Cohort
Study. J Clin Endocrinol Metab 2015; 100: 2763–8.
40 The Fibrinogen Studies Collaboration. Regression dilution
methods for meta-analysis: assessing long-term variability in
plasma fibrinogen among 27 247 adults in 15 prospective
studies. Int J Epidemiol 2006; 35: 1570–8.
41 Knott C, Bell S, Britton A. Alcohol consumption and the risk
of type 2 diabetes: a systematic review and dose-response
meta-analysis of more than 1.9 million individuals from 38
observational studies. Diabetes Care 2015; 38: 1804–12.
42 Chikritzhs T, Stockwell T, Naimi T, Andreasson S, Dangardt
F, Liang W. Has the leaning tower of presumed health benefits
from “moderate” alcohol use finally collapsed? Addiction
2015; 110: 726–7.
43 Tabak AG, Kivim€aki M, Brunner EJ et al. Changes in C-
reactive protein levels before type 2 diabetes and cardiovas-
cular death: the Whitehall II study. Eur J Endocrinol 2010;
163: 89–95.
44 Metti AL, Aizenstein H, Yaffe K et al. Trajectories of peripheral
interleukin-6, structure of the hippocampus, and cognitive
impairment over 14 years in older adults. Neurobiol Aging
2015; 36: 3038–44.
45 Janssen I, Landay AL, Ruppert K, Powell LH. Moderate wine
consumption is associated with lower hemostatic and inflam-
matory risk factors over 8 years: the study of women’s health
across the nation (SWAN). Nutr Aging Amst Neth 2014; 2: 91.
46 Marmot M, Brunner E. Cohort Profile: the Whitehall II study.
Int J Epidemiol 2005; 34: 251–6.
47 Britton A, O’Neill D, Bell S. Underestimating the alcohol
content of a glass of wine: the implications for estimates of
mortality risk. Alcohol Alcohol 2016; doi: 10.1093/alcalc/
agw027 [Epub ahead of print].
48 Rehm J, Irving H, Ye Y, Kerr WC, Bond J, Greenfield TK. Are
lifetime abstainers the best control group in alcohol epidemi-
ology? On the stability and validity of reported lifetime
abstention. Am J Epidemiol 2008; 168: 866–71.
49 Myers GL, Rifai N, Tracy RP et al. CDC/AHA workshop on
markers of inflammation and cardiovascular disease: appli-
cation to clinical and public health practice: report from the
S. Bell et al. Alcohol and cytokine trajectories
84 ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Journal of Internal Medicine, 2017, 281; 75–85
Laboratory Science Discussion Group. Circulation 2004; 110:
e545–9.
50 Tabak AG, Carstensen M, Witte DR et al. Adiponectin trajec-
tories before type 2 diabetes diagnosis: Whitehall II study.
Diabetes Care 2012; 35: 2540–7.
51 Britton A, Marmot M. Different measures of alcohol con-
sumption and risk of coronary heart disease and all-cause
mortality: 11-year follow-up of the Whitehall II Cohort Study.
Addiction 2004; 99: 109–16.
52 Bell S, Britton A. Drinking pattern during midlife and risk of
developing depression during 28 years of follow-up: a
prospective cohort study. Drug Alcohol Depend 2015; 155:
111–7.
53 The Interleukin-6 Receptor Mendelian Randomisation Anal-
ysis (IL6R MR) Consortium. The interleukin-6 receptor as a
target for prevention of coronary heart disease: a mendelian
randomisation analysis. Lancet 2012; 379: 1214–24.
54 Muralidharan S, Ambade A, Fulham MA, Deshpande J,
Catalano D, Mandrekar P. Moderate alcohol induces stress
proteins HSF1 and hsp70 and inhibits proinflammatory
cytokines resulting in endotoxin tolerance. J Immunol 2014;
193: 1975–87.
55 Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mech-
anisms, molecules and clinical significance. Trends Immunol
2009; 30: 475–87.
56 Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge
drinking increases serum endotoxin and bacterial DNA levels
in healthy individuals. PLoS One 2014; 9: e96864.
57 Vijay-Kumar M, Aitken JD, Carvalho FA et al. Metabolic
syndrome and altered gut microbiota in mice lacking Toll-Like
receptor 5. Science 2010; 328: 228–31.
58 Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia
initiates obesity and insulin resistance. Diabetes 2007; 56:
1761–72.
59 Reactive C, Protein Coronary Heart Disease Genetics Collab-
oration. Association between C reactive protein and coronary
heart disease: mendelian randomisation analysis based on
individual participant data. BMJ 2011; 342: d548.
60 Ng Fat L, Cable N, Shelton N. Worsening of health and a
cessation or reduction in alcohol consumption to special
occasion drinking across three decades of the life course.
Alcohol Clin Exp Res 2015; 39: 166–74.
61 Leclercq S, De Saeger C, Delzenne N, de Timary P, St€arkel P.
Role of inflammatory pathways, blood mononuclear cells, and
gut-derived bacterial products in alcohol dependence. Biol
Psychiatry 2014; 76: 725–33.
62 Pawelec G, Goldeck D, Derhovanessian E. Inflammation,
ageingandchronicdisease.CurrOpin Immunol2014;29:23–8.
63 Dwarkasing J., Marks DL, Witkamp R., van Norren K.
Hypothalamic inflammation and food intake regulation dur-
ing chronic illness. Peptides 2016; 77: 60–6.
64 Verrill C, Markham H, Templeton A, Carr NJ, Sheron N.
Alcohol-related cirrhosis—early abstinence is a key factor in
prognosis, even in the most severe cases. Addiction 2009;
104: 768–74.
65 Powell WJ, Klatskin G. Duration of survival in patients with
Laennec’s cirrhosis: influence of alcohol withdrawal, and
possible effects of recent changes in general management of
the disease. Am J Med 1968; 44: 406–20.
66 Naimi TS, Brown DW, Brewer RD et al. Cardiovascular risk
factors and confounders among nondrinking and moderate-
drinking U.S. adults. Am J Prev Med 2005; 28: 369–73.
67 Ng Fat L, Shelton N. Associations between self-reported
illness and non-drinking in young adults. Addiction 2012;
107: 1612–20.
68 Rehm J, Shield KD, Roerecke M, Gmel G. Modelling the
impact of alcohol consumption on cardiovascular disease
mortality for comparative risk assessments: an overview.
BMC Public Health 2016; 16: 1–9.
69 Bellis MA, Hughes K, Jones L et al. Holidays, celebrations,
and commiserations: measuring drinking during feasting and
fasting to improve national and individual estimates of
alcohol consumption. BMC Med 2015; 13: 113.
70 Roerecke M, Rehm J. Alcohol consumption, drinking pat-
terns, and ischemic heart disease: a narrative review of meta-
analyses and a systematic review and meta-analysis of the
impact of heavy drinking occasions on risk for moderate
drinkers. BMC Med 2014; 12: 182.
71 Batty GD, Shipley M, Tabak A et al. Generalizability of
occupational cohort study findings. Epidemiology 2014; 25:
932–3.
Correspondence: Steven Bell, Department of Public Health and
Primary Care, Strangeways Research Laboratory, University of
Cambridge, Worts Causeway, Cambridge CB1 8RN, UK.
(fax: +44 (0)1223 748658; e-mail: scb81@medschl.cam.ac.uk).
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Descriptive information of changes in
inflammatory markers and alcohol consumption
during follow-up by drinking typology.
Table S2. Fixed-effect coefficients from linear
mixed model regression for association of current
drinking habits and inflammatory marker trajec-
tories during the following 12 years.
Table S3. Fixed-effect coefficients from linear
mixed model regression for association of current
drinking category and fibrinogen trajectories dur-
ing the following 7 years.
Table S4. Fixed-effect coefficients from linear
mixed model regression for association of ten year
drinking typologies and fibrinogen trajectories dur-
ing the following 7 years.
Figure S1. Model predicted C-reactive protein,
interleukin-6 and interleukin-1 receptor antago-
nist trajectories by current drinking status.
Figure S2. Multivariable adjusted model predicted
fibrinogen trajectories by current drinking status
(left) and ten year drinking typology (right).
S. Bell et al. Alcohol and cytokine trajectories
ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. 85
Journal of Internal Medicine, 2017, 281; 75–85
